Lauren A Dalvin1, Steven B Thom, Joaquín J García, Hind J Fadel, Keith H Baratz. 1. *Department of Ophthalmology, Mayo Clinic, Rochester, MN; †Thom Eye & Laser Clinic, Fargo, ND; Departments of ‡Laboratory Medicine and Pathology; and §Infectious Disease, Mayo Clinic, Rochester, MN.
Abstract
PURPOSE: To describe the first-documented case of histoplasma scleritis in an immunocompetent patient. METHODS: Medical and pathological records of the patient described were reviewed. RESULTS: A 77-year-old immunocompetent man presented with necrotizing scleritis. Biopsy was consistent with histoplasma species, and culture results confirmed a causative agent of Histoplasma capsulatum. The patient required a long course of treatment, which included topical voriconazole and amphotericin, oral itraconazole and voriconazole, intravenous amphotericin, and periocular voriconazole and amphotericin. After 8 months of treatment, the patient's scleritis resolved, and he maintained good visual acuity. CONCLUSIONS: To our knowledge, this is the second report of histoplasma scleritis in the literature and the first report in an immunocompetent patient.
PURPOSE: To describe the first-documented case of histoplasma scleritis in an immunocompetent patient. METHODS: Medical and pathological records of the patient described were reviewed. RESULTS: A 77-year-old immunocompetent man presented with necrotizing scleritis. Biopsy was consistent with histoplasma species, and culture results confirmed a causative agent of Histoplasma capsulatum. The patient required a long course of treatment, which included topical voriconazole and amphotericin, oral itraconazole and voriconazole, intravenous amphotericin, and periocular voriconazole and amphotericin. After 8 months of treatment, the patient's scleritis resolved, and he maintained good visual acuity. CONCLUSIONS: To our knowledge, this is the second report of histoplasma scleritis in the literature and the first report in an immunocompetent patient.